Uveal Melanoma – a review of treatment methods Review article

Main Article Content

Aleksandra Domańska
Daria Piekarz
Natalia Pijas
Barbara Pieniążek
Halina Piecewicz-Szczęsna


Uveal melanoma is the most common primary intraocular malignancy. In Europe, the incidence of uveal melanoma is approximately 8 cases per million people per year. In about 50% of cases, uveal melanoma metastasizes. Scientific papers on uveal melanoma published between 1 January 2018 – 1 March 2023, available in the PubMed database were analysed. Currently, methods such as enucleation, transpupillary thermotherapy, photodynamic therapy, eye plaque brachytherapy, proton beam therapy and stereotactic surgery are used to treat this cancer. In this paper we summarize the current knowledge about the classic treatment methods and the promising novel ones. 


Download data is not yet available.

Article Details

How to Cite
Domańska A, Piekarz D, Pijas N, Pieniążek B, Piecewicz-Szczęsna H. Uveal Melanoma – a review of treatment methods. Ophthatherapy [Internet]. 2023Dec.31 [cited 2024Jul.18];10(4):245-52. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/2795
Conservative treatment
Author Biography

Halina Piecewicz-Szczęsna, Chair and Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, Poland 



1. Toro MD, Gozzo L, Tracia L et al. New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review. Biomedicines. 2021; 9(10): 1311. https://doi.org/10.3390/biomedicines9101311.
2. Schefler AC, Kim RS. Recent advancements in the management of retinoblastoma and uveal melanoma. Fac Rev. 2021; 10: 51. https://doi.org/10.12703/r/10-51.
3. Branisteanu D, Bogdanici C, Branisteanu D et al. Uveal melanoma diagnosis and current treatment options (Review). Exp Ther Med. 2021; 22(6): 1428. https://doi.org/10.3892/etm.2021.10863.
4. Singh M, Durairaj P, Yeung J. Uveal Melanoma: A Review of the Literature. Oncol Ther. 2018; 6(1): 87-104. https://doi.org/10.1007/s40487-018-0056-8.
5. Hope-Stone L, Brown SL, Heimann H et al. Comparison between patient-reported outcomes after enucleation and proton beam radiotherapy for uveal melanomas: a 2-year cohort study. Eye (Lond). 2019; 33(9): 1478-84. https://doi.org/10.1038/s41433-019-0440-0.
6. Damato B, Hope-Stone L, Cooper B et al. Patient-Reported Outcomes and Quality of Life after Treatment for Choroidal Melanoma. Ocul Oncol Pathol. 2019; 5(6): 402-11. https://doi.org/10.1159/000496927.
7. Negretti GS, Gurudas S, Gallo B et al. Survival analysis following enucleation for uveal melanoma. Eye (Lond). 2022; 36(8): 1669-74. https://doi.org/10.1038/s41433-021-01710-y .
8. Messer J, Zuhour R, Haque W et al. Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database. J Contemp Brachytherapy. 2020; 12(4): 303-10. https://doi.org/10.5114/jcb.2020.98108.
9. Sayan M, Mamidanna S, Oncel D et al. Clinical management of uveal melanoma: a comprehensive review with a treatment algorithm. Radiat Oncol J. 2020; 38(3): 162-9. https://doi.org/10.3857/roj.2020.00318.
10. Mazloumi M, Dalvin LA, Abtahi S-H et al. Photodynamic Therapy in Ocular Oncology. J Ophthalmic Vis Res. 2020; 15(4): 547-58. https://doi.org/10.18502/jovr.v15i4.7793.
11. Maheshwari A, Finger PT. Laser treatment for choroidal melanoma: Current concepts. Surv Ophthalmol. 2022; 68(2): 211-24. https://doi.org/10.1016/j.survophthal.2022.05.002.
12. Blasi MA, Pagliara MM, Lanza A et al. Photodynamic Therapy in Ocular Oncology. Biomedicines. 2018; 6(1): 17. https://doi.org/10.3390/biomedicines6010017.
13. Foti PV, Travali M, Farina R et al. Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: treatment indications and complications. Insights Imaging. 2021; 12(1): 67. https://doi.org/10.1186/s13244-021-01001-w.
14. Reichstein D, Karan K. Plaque brachytherapy for posterior uveal melanoma in 2018. Curr Opin Ophthalmol. 2018; 29(3): 191-8. https://doi.org/10.1097/ICU.0000000000000468.
15. Fili M, Astrahan M, Stålhammar G. Long-term outcomes after enucleation or plaque brachytherapy of choroidal melanomas touching the optic disc. Brachytherapy. 2021; 20(6): 1245-56.
16. Maheshwari A, Finger PT. A 12-Year Study of Slotted Palladium-103 Plaque Radiation Therapy for Choroidal Melanoma: Near, Touching, or Surrounding the Optic Nerve. Am J Ophthalmol. 2018; 188: 60-9. https://doi.org/10.1016/j.ajo.2018.01.025.
17. Simpson ER, Gallie B, Laperrierre N et al. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014; 13(1): 1-14. https://doi.org/10.1016/j.brachy.2013.11.008.
18. Filì M, Trocme E, Bergman L et al. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm. Br J Ophthalmol. 2020; 104(1): 26-32. https://doi.org/10.1136/bjophthalmol-2018-313419.
19. Filì M, Trocme E, Herrspiegel C et al. Effect of plaque brachytherapy dose and dose rate on risk for disease-related mortality in 1238 patients with choroidal melanoma. Br J Ophthalmol. 2021; 105(1): 57-62. https://doi.org/10.1136/bjophthalmol-2019-315722.
20. Buonanno F, Conson M, de Almeida Ribeiro C et al. Local tumor control and treatment related toxicity after plaque brachytherapy for uveal melanoma: A systematic review and a data pooled analysis. Radiother Oncol. 2022; 166: 15-25. https://doi.org/10.1016/j.radonc.2021.11.007.
21. The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma. Arch Ophthalmol. 2006; 124(12): 1684-93. https://doi.org/10.1001/archopht.124.12.1684.
22. Fang R, Wang H, Li Y et al. Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy. BMC Ophthalmol. 2021; 21(1): 137. https://doi.org/10.1186/s12886-021-01898-3.
23. Ghassemi F, Sheibani S, Arjmand M et al. Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas. Clin Ophthalmol. 2020; 14: 339-46. https://doi.org/10.2147/OPTH.S235265.
24. Karimi S, Arabi A, Siavashpour Z et al. Efficacy and complications of ruthenium-106 brachytherapy for uveal melanoma: a systematic review and meta-analysis. J Contemp Brachytherapy. 2021; 13(3): 358-64. https://doi.org/10.5114/jcb.2021.106191.
25. Reichstein DA, Brock AL. Radiation therapy for uveal melanoma: a review of treatment methods available in 2021. Curr Opin Ophthalmol. 2021; 32(3): 183-90. https://doi.org/10.1097/ICU.0000000000000761.
26. Cennamo G, Montorio D, D’Andrea L et al. Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy. Front Oncol. 2022; 11: 754108. https://doi.org/10.3389/fonc.2021.754108.
27. Rospond-Kubiak I, Wróblewska-Zierhoffer M, Twardosz-Pawlik H et al. Ruthenium brachytherapy for uveal melanoma – single institution experience J Contemp Brachytherapy. 2017; 9(6): 548-52. https://doi.org/10.5114/jcb.2017.72606.
28. Wang H, Zhang R, Wang Y et al. Retrospective analysis of secondary enucleation for uveal melanoma after plaque radiotherapy. BMC Ophthalmol. 2022; 22(1): 163. https://doi.org/10.1186/s12886-022-02387-x.
29. Takiar V, Voong KR, Gombos DS et al. A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. Pract Radiat Oncol. 2015; 5(3): e169-76. https://doi.org/10.1016/j.prro.2014.09.005.
30. Toutée A, Angi M, Dureau S et al. Long-Term Visual Outcomes for Small Uveal Melanoma Staged T1 Treated by Proton Beam Radiotherapy. Cancers (Basel). 2019; 11(8): 1047. https://doi.org/10.3390/cancers11081047.
31. Messineo D, Barile G, Morrone S et al. Meta-analysis on the utility of radiotherapy for the treatment of Ocular Melanoma. Clin Ter. 2020; 170(1): e89-98. https://doi.org/10.7417/CT.2020.2195.
32. Intraocular (Uveal) Melanoma Treatment (PDQ®): Health Professional Version – PubMed. 2021.
33. van Beek JGM, Ramdas WD, Angi M et al. Local tumour control and radiation side effects for fractionated stereotactic photon beam radiotherapy compared to proton beam radiotherapy in uveal melanoma. Radiother Oncol. 2021; 157: 219-24. https://doi.org/10.1016/j.radonc.2021.01.030.
34. Gollrad J, Rabsahl C, Riechardt AI et al. Quality of life and treatment-related burden during ocular proton therapy: a prospective trial of 131 patients with uveal melanoma. Radiat Oncol. 2021; 16(1): 174. https://doi.org/10.1186/s13014-021-01902-6.
35. Giannaccare G, Bernabei F, Angi M et al. Iatrogenic Ocular Surface Diseases Occurring during and/or after Different Treatments for Ocular Tumours. Cancers (Basel). 2021; 13(8): 1933. https://doi.org/10.3390/cancers13081933.
36. Sorour OA, Mignano JE, Duker JS. Gamma Knife radiosurgery for locally recurrent choroidal melanoma following plaque radiotherapy. Int J Retina Vitreous. 2018; 4: 23. https://doi.org/10.1186/s40942-018-0123-1.
37. Zhao L, Xia W, Zhang Y et al. Efficacy and Safety of Immune Checkpoint Blockades in the Treatment of Ocular Melanoma: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11: 781162. https://doi.org/10.3389/fonc.2021.781162.
38. Sacco JJ, Kalirai H, Kenyani J et al. Recent breakthroughs in metastatic uveal melanoma: a cause for optimism? Future Oncol. 2018; 14(14): 1335-8. https://doi.org/10.2217/fon-2018-0116.
39. Fu Y, Xiao W, Mao Y. Recent Advances and Challenges in Uveal Melanoma Immunotherapy. Cancers (Basel). 2022; 14(13): 3094. https://doi.org/10.3390/cancers14133094.
40. Wang S, Chen B, Ouyang L et al. A Novel Stimuli-Responsive Injectable Antibacterial Hydrogel to Achieve Synergetic Photothermal/ Gene-Targeted Therapy towards Uveal Melanoma. Adv Sci (Weinh). 2021; 8(18): e2004721. https://doi.org/10.1002/advs.202004721.
41. Xie L, Yue W, Ibrahim K et al. A Long-Acting Curcumin Nanoparticle/In Situ Hydrogel Composite for the Treatment of Uveal Melanoma. Pharmaceutics. 2021; 13(9): 1335. https://doi.org/10.3390/pharmaceutics13091335.
42. Zhang L, Huang X, Guo T et al. Study of Cinobufagin as a Promising Anticancer Agent in Uveal Melanoma Through Intrinsic Apoptosis Pathway. Front Oncol. 2020; 10: 325. https://doi.org/10.3389/fonc.2020.00325.
43. Zhao C-X, Zeng C-M, Wang K et al. Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence? Acta Pharmacol Sin. 2021; 42(2): 179-88. https://doi.org/10.1038/s41401-020-0441-3.